PARIS--(BUSINESS WIRE)-- Regulatory News: MERCIALYS (Paris:MERY): Nombre d’actions composant le capital Nombre total de droits de vote Nombre total de droits de vote exerçables en assemblée générale 93 886 501 93 886 501 93 522 214 Consultez la version source sur businesswire.com :
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
>Outperform rating and target price of € 35.50 unchanged - The Q1 2024 revenue release was fully in line with our expectations (€ 141.4m vs € 144.9m estimated). The group also confirmed its 2024 guidance and that for 2030. We maintain our Outperform rating and target price of € 35.5 still based on the average of a sum-of-the-parts (€ 35.4) and a DCF (€ 35.6 and unchanged growth to infinity of 1.80%). The current market capitalisation points to a certain upside from b...
>Opinion Surperformance et OC 35.50 € inchangés - La publication du chiffre d’affaires du T1 24 est ressortie parfaitement en ligne avec nos anticipations (141.4 M€ vs 144.9 M€ estimés). Le groupe confirme également ses guidances 2024 ainsi que celles de 2030. Nous maintenons notre recommandation Surperformance et notre objectif de cours de 35.5 € toujours fondé sur une moyenne entre une somme des parties (35.4 €) et un DCF (35.6 € et taux de croissance à l’infini in...
Cellectis nomme Arthur Stril directeur financier par intérim NEW YORK, 02 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, a annoncé aujourd'hui la démission de M. Bing Wang de son poste au sein de la Société avec effet immédiat, et la nomination concomitante de M. Arthur Stril en tant que directeur financier par intérim, en remplacement de M. ...
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of the Company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Devel...
Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...
>Q1 2024 revenue fully in line - The group has just announced Q1 2024 revenue of € 141.4m, in line with our forecast of € 144.9m, down 8% vs Q1 2023 and 6% at constant forex. This trend was largely due to an unfavourable comparison base linked to the more limited contribution from a number of assets that benefited from revenues upstream of long-term contracts and which have since entered the long-term contractual framework from Q2 2023, in Finland and Australia. Prod...
>Un chiffre d’affaires T1 24 parfaitement en ligne - Le groupe vient d’annoncer un chiffre d’affaires de 141,4 M€ au T1 24, en ligne avec nos attentes de 144.9 M€, en recul de 8% par rapport au T1 23 et de 6% à taux de change constants. Cette évolution s’explique principalement par un effet de base défavorable lié à la moindre contribution de plusieurs actifs ayant bénéficié de revenus en amont de contrats à long terme et entrés depuis dans le cadre contractuel de lo...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 • Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and investment agreements with AstraZeneca • Cécile Chartier, Ph.D., appointed as a director of the Cellectis’ Board of Directors • Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) • Cash position of $156 million ...
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 • Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH) • Signature d’un accord de collaboration stratégique et d'accords d’investissement avec AstraZeneca • Nomination du docteur Cécile Chartier, Ph.D. au conseil d’administration • Tirage de la deuxième tranche de 15 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Eu...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
>Q1 organic growth below expectations - Alten yesterday reported Q1 revenue of € 1,067m, with organic growth of 0.8%, below expectations (ODDO BHF: 3.1% organic; consensus: 2.3% organic; Q4: 5.8% organic). The performance was again driven by France, which posted organic growth of 6.0% (ODDO BHF: 8.0% organic), albeit at a much slower pace than in Q4 (11.3% organic). The performance was driven by the Aero, Defence, Automotive and Energy sectors, while Retail and Bank,...
>Croissance org T1 inférieure aux attentes - Alten a publié hier un CA T1 de 1 067 M€, avec une croissance org. de 0.8%, inférieure aux attentes (ODDO BHF: 3.1% org ; css: 2.3% org ; T4: 5.8% org). Cette performance est de nouveau tirée par la France qui est en croissance org. de 6.0%, (ODDO BHF :8.0% org) mais en net ralentissement par rapport au T4 (11.3% org). Cette performance a été tirée par les secteurs Aero, Défense, Automobile et Energie alors que le secteur ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.